What's Going On With Bluebird Bio Stock?

Zinger Key Points
  • Bluebird Bio shares are trading higher Monday after the company presented updated data from its gene therapy program.
  • The news comes after Bluebird Bio shares tumbled on Friday.

Bluebird Bio Inc BLUE shares are trading higher Monday after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

What Happened: Bluebird Bio said the data showed sustained treatment effect, reduced iron management burden and improved quality of life measures in patients with beta-thalassemia who require regular red blood cell transfusions following treatment with betibeglogene autotemcel, which is FDA approved in the U.S. and marketed as ZYNTEGLO.

"Long-term results presented at ASH 2023 showed durable transfusion independence and a continued positive safety profile in patients with beta-thalassemia treated with our beti-cel gene therapy through up to nine years of follow-up," said Richard Colvin, chief medical officer of Bluebird Bio.

The news comes after Bluebird Bio shares tumbled on Friday after the FDA added a black box warning for patients treated with Lyfgenia regarding the risk of hematologic malignancy.

See Also: Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease

BLUE Price Action: Bluebird Bio shares were up 2.45% at $2.93 at the time of publication, according to Benzinga Pro.

Photo: 3844328 from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksSmall CapMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!